Edit and convert PDFs with ease thanks to this A$37 app
The following content is brought to you by Mashable partners. If you buy a product featured here, we may earn an affiliate commission or other compensation.
TL;DR: Take control of your documents with PDF Converter and Editor. Easily convert, edit, and manage PDFs with this lifetime license, now just A$37 with code SAVE20 through June 1.
Tired of the daily PDF struggle? With PDF Converter and Editor, you can easily switch between formats, edit text, and organize your documents like a pro. And right now, you can secure a lifetime subscription for only A$37 (reg. A$156) with code SAVE20 before June 1.
Stop jumping through hoops when it comes to PDFs. PDF Converter and Editor lets you tackle this pesky file format easily on one handy platform. Convert PDFs to Word, Excel, JPG, and more files — or turn other formats into PDFs with just a few clicks.
PDF Converter offers lightning-fast conversions without sacrificing quality. You'll enjoy high-quality output, so you can confidently convert files for any purpose.
This app does more than convert PDFs — it's packed with extra tools to make working with PDFs a breeze. Built-in OCR technology can extract text from image-based files. And merging, splitting, or compressing documents is equally straightforward.
Need to fill out an existing PDF? It's easy to fill out forms with text, check boxes, shapes, and annotations all on PDF Converter. Want to just grab the images off a PDF file? That's just as simple — you can extract all JPGs and PNGs from a PDF with just one click.
If you're dealing with sensitive data, PDF Converter lets you lock or unlock your files, add password protection, and even encrypt sensitive information for peace of mind.
Need to enhance your PDF? This app makes it easy to add customizable watermarks and shapes as needed.
Manage, edit, and convert PDFs with PDF Converter and Editor for just A$37 using code SAVE20 through June 1.
StackSocial prices subject to change.
Opens in a new window
Credit: Acethinker
PDF Converter & Editor: Lifetime License
AU$37 AU$156 Save AU$119
Get Deal
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Cleo Diagnostics (ASX:COV) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. Given this risk, we thought we'd take a look at whether Cleo Diagnostics (ASX:COV) shareholders should be worried about its cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. When Cleo Diagnostics last reported its December 2024 balance sheet in February 2025, it had zero debt and cash worth AU$7.3m. In the last year, its cash burn was AU$2.8m. That means it had a cash runway of about 2.6 years as of December 2024. That's decent, giving the company a couple years to develop its business. The image below shows how its cash balance has been changing over the last few years. Check out our latest analysis for Cleo Diagnostics While Cleo Diagnostics did record statutory revenue of AU$211k over the last year, it didn't have any revenue from operations. To us, that makes it a pre-revenue company, so we'll look to its cash burn trajectory as an assessment of its cash burn situation. During the last twelve months, its cash burn actually ramped up 58%. Oftentimes, increased cash burn simply means a company is accelerating its business development, but one should always be mindful that this causes the cash runway to shrink. Cleo Diagnostics makes us a little nervous due to its lack of substantial operating revenue. So we'd generally prefer stocks from this list of stocks that have analysts forecasting growth. While Cleo Diagnostics does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Companies can raise capital through either debt or equity. Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations. Cleo Diagnostics' cash burn of AU$2.8m is about 5.4% of its AU$51m market capitalisation. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to simply borrow some money. As you can probably tell by now, we're not too worried about Cleo Diagnostics' cash burn. For example, we think its cash runway suggests that the company is on a good path. Although its increasing cash burn does give us reason for pause, the other metrics we discussed in this article form a positive picture overall. Based on the factors mentioned in this article, we think its cash burn situation warrants some attention from shareholders, but we don't think they should be worried. On another note, we conducted an in-depth investigation of the company, and identified 3 warning signs for Cleo Diagnostics (1 is a bit concerning!) that you should be aware of before investing here. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts) — Investing narratives with Fair Values A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029. By Agricola – Community Contributor Fair Value Estimated: CA$12.29 · 0.9% Overvalued DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts By WynnLevi – Community Contributor Fair Value Estimated: $195.39 · 0.9% Overvalued Historically Cheap, but the Margin of Safety Is Still Thin By Mandelman – Community Contributor Fair Value Estimated: SEK232.58 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
Apple Watch deals are heating up ahead of Prime Day — save up to $150
All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. Best early Prime Day Apple Watch deals Best Series 10 deal Apple Watch Series 10 (42mm, GPS) $319 (save $80) Get Deal Best Ultra deal Apple Watch Ultra 2 (49mm, GPS + cellular) $729.99 (save $69.01) Get Deal Best SE deal Apple Watch SE (44mm, GPS) $219 (save $60) Get Deal You don't need a smartwatch to tell you that Prime Day is a great time to pick up an Apple Watch. This year, the Prime member-exclusive sale runs a whopping four days, from July 8 to July 11. But if you want to score some savings Apple Watches (and Apple in general, for that matter), you don't have to wait. Typically, Apple deals aren't officially affiliated with the sale, which means that non-Prime members can enjoy the savings, too. While Prime Day proper does tend to bring a higher volume of record low prices, the weeks leading up to the sale have deals ranging from decent to great. Case in point: each model of the Apple Watch is available at a discounted price, with markdowns ranging from $60 to $150. SEE ALSO: Walmart's anti-Prime Day sale is extra competitive this year With Apple Watches, you'll tend to score the best savings if you're not picky about colorways. While none of the deals below are rare (in other words, necessary to jump on ASAP), it's a solid lineup for folks who don't want to wait for July 8. Our pick: Apple Watch Series 10 (42mm, GPS) $299 at Amazon $399 Save $100 Get Deal Check out our full review of the Apple Watch Series 10. The Apple Watch Series 10 frequently gets discounted at Amazon. Shortly after its release last fall, the smartwatch received a $20 price cut, and dropped to the $330 range before the year's end. At $319, this is a better deal than average, especially considering it's Mashable's top pick for a smartwatch fitness tracker. If you want the absolute best price, you'll have to wait until this watch drops to $299. We like the Series 10 thanks to its suite of health tracking capabilities, including a heart rate monitor, sleep tracker, menstrual cycle tracker, and pedometer (the blood oxygen sensor is the main feature that's missing). It also has an ultra bright and lightweight display. Apple Watch Series 10 (46mm, GPS) — $359 $429 (save $70) Apple Watch Series 10 (42mm, GPS + cellular) — $429 $499 (save $70) Apple Watch Series 10, Milanese loop (42mm, GPS + cellular) — $699 $749 (save $150) Apple Watch Ultra 2 (49mm, GPS + cellular) — $729.99 $799 (save $69.01) Apple Watch SE, 2nd Gen (40mm, GPS) — $189 $249 (save $60) Apple Watch SE, 2nd Gen (44mm, GPS) — $219 $279 (save $60) Apple Watch SE, 2nd Gen (40mm, GPS + cellular) — $239 $299 (save $60) Apple Watch SE, 2nd Gen (44mm, GPS + cellular) — $269 $329 (save $60) Apple AirTag (4-Pack) — $74.99 (List Price $99.00) Samsung Galaxy Watch 7 (Wi-Fi, 40mm, S/M Green) — $199.99 (List Price $299.99) Dyson V15 Detect Plus Cordless Vacuum Cleaner (Yellow/Nickel) — $649.99 (List Price $749.99) Apple 2025 MacBook Air 13-inch Laptop — $849.00 (List Price $999.00) Hisense 55" Class QD6 Series (2025 Model) QLED 4K UHD TV — $259.99 (List Price $379.99)
Yahoo
a day ago
- Yahoo
Regencell's 82,000% Surge: The $33 Billion Stock Rally That Nobody Can Explain
When Regencell Bioscience (NASDAQ:RGC) surged 82,000%, it wasn't on the back of a blockbuster drug or FDA approval. It was something far stranger. A small, loss-making traditional Chinese medicine firm with a vacant chief medical officer post and no revenue catalyst suddenly became a $33 billion paper giantat least for a few days. At the peak, founder and CEO Yat-Gai Au's stake eclipsed the wealth of Hong Kong's richest tycoons. He wasn't at the office. No press conference. No update. Then came the crash. As of June 26, the stock has fallen 74%, dragging Au's fortune down to $8.6 billion. Warning! GuruFocus has detected 2 Warning Signs with RGC. The company's fundamentals don't justify its viral rise. Regencell markets herbal formulas for ADHD and autism, developed by Au's father, under the trademark Brain Theory. It posted net losses of $4.4 million in fiscal 2024 and $6.1 million in 2023. Yet it managed to outshine every major healthcare brand on Instagramthanks in part to Taylor Swift ticket giveaways. Its second-largest shareholder? A firm tied to Zoom early investor Samuel Chen. Chen, along with his family, also controls Taiwan's Polaris Group and holds a major stake in IC firm Sonix Technology. None of them are talking. And neither is Regencell. Now regulators might start asking the questions retail investors already are. With no news, no insider filings, and no scientific breakthroughs, the stock's behavior has triggered interest from market observers. Both the SEC and Finra have automated tools for flagging anomalies like this, and experts say it's exactly the kind of movement that draws scrutiny. On June 4, the SEC even floated a proposal to tighten rules on foreign private issuerscompanies like Regencell that operate overseas but trade in the U.S. Whether the rally was driven by low float dynamics, social media virality, or something more problematic remains to be seen. But one thing's certain: for investors, this was a $33 billion lesson in how fast the music can stop. This article first appeared on GuruFocus. Sign in to access your portfolio
